SIMPONI
Biological
Janssen Research & Development, LLC
Total Payments
$7.6M
Transactions
9,228
Doctors
2,389
Companies
6
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $4.4M | 1,881 | 3 |
| 2023 | $1.5M | 615 | 9 |
| 2022 | $265,010 | 89 | 26 |
| 2021 | $17,732 | 28 | 28 |
| 2020 | $27,572 | 36 | 24 |
| 2019 | $150,756 | 5,287 | 2,002 |
| 2018 | $649,696 | 619 | 194 |
| 2017 | $603,802 | 673 | 240 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $7.0M | 2,703 | 91.7% |
| Consulting Fee | $462,486 | 87 | 6.1% |
| Food and Beverage | $108,425 | 6,338 | 1.4% |
| Travel and Lodging | $36,207 | 81 | 0.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $18,750 | 14 | 0.2% |
| Space rental or facility fees (teaching hospital only) | $7,500 | 5 | 0.1% |
Payments by Type
Research
$7.0M
2,703 transactions
General
$633,368
6,525 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| 78934804UCO2001 | Janssen Research & Development, LLC | $5.7M | 0 |
| A Multicenter, Open-Label Trial of Intravenous Golimumab, a Human Anti-TNFa Antibody, in Pediatric Subjects With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy | Janssen Research & Development, LLC | $524,096 | 0 |
| A Multi Center Open Label Trial of Intravenous Golimumab a Human AntiTNFa Antibody in Pediatric Subjects With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy | Janssen Research & Development, LLC | $296,573 | 0 |
| A Phase 3 Randomized Open Label Study to Assess the Efficacy Safety and Pharmacokinetics of Golimumab Treatment a Human antiTNFa Monoclonal Antibody Administered Subcutaneously in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis | Janssen Research & Development, LLC | $147,546 | 0 |
| A Phase 1b Open-Label Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human anti-TNFa Antibody, in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis | Janssen Research & Development, LLC | $93,169 | 0 |
| Golimumab IV solution being administered intravenously for treatment of pateints with Psoriatic Arthritis- trial project name CNTO148PSA3001 | Janssen Research & Development, LLC | $84,510 | 0 |
| Evaluating periodontal disease in RA patients starting anti-TNF therapy | Janssen Research & Development, LLC | $41,705 | 0 |
| A Retrospective Review of Treatments in Pregnant Psoriatic Arthritis Patients | Janssen Research & Development, LLC | $25,600 | 0 |
| A Phase 3 Randomized, Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Golimumab Treatment, a Human anti-TNF Monoclonal Antibody, Administered Subcutaneously in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis | Janssen Research & Development, LLC | $18,500 | 0 |
| The Use of Golimumab in anti-TNF experienced Patients | Janssen Research & Development, LLC | $17,888 | 0 |
| Biomarker probe set to determine golimumab response | Janssen Research & Development, LLC | $13,574 | 0 |
| A Phase 3 Randomized, Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Golimumab Treatment, a Human anti-TNFa Monoclonal Antibody, Administered Subcutaneously in Pediatric Participants with Moderately to Severely ActiveUlcerative Colitis | Janssen Research & Development, LLC | $13,100 | 0 |
| A Phase 1b Study to Evaluate SIMPONI golimumab Therapy in Children Adolescents and Young Adults with Pre Symptomatic Type 1 Diabetes | Janssen Research & Development, LLC | $10,158 | 0 |
| A Phase 1b Study to Evaluate SIMPONI (golimumab) Therapy in Children, Adolescents and Young Adults with Pre-Symptomatic Type 1 Diabetes | Janssen Research & Development, LLC | $8,500 | 0 |
| A Phase 1b Open Label Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab a Human anti TNFa Antibody in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis | Janssen Research & Development, LLC | $5,910 | 0 |
| A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFa Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis | Janssen Research & Development, LLC | $4,594 | 0 |
| Golimumab IV solution being administered intravenously for treatment of patients with Psoriatic Arthritis- trial project name CNTO148PSA3001 | Janssen Research & Development, LLC | $2,720 | 0 |
Top Doctors Receiving Payments for SIMPONI
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Seattle, WA | $7.2M | 2,743 |
| , MD | Pediatric Emergency Medicine | Buffalo, NY | $23,083 | 4 |
| , M.D | Internal Medicine | Boston, MA | $15,074 | 17 |
| , MD | Gastroenterology | Suwanee, GA | $14,144 | 16 |
| , MD | Gastroenterology | Houston, TX | $12,972 | 15 |
| , MD | Gastroenterology | Chicago, IL | $9,004 | 11 |
| , MD | Clinical Pathology/Laboratory Medicine | Philadelphia, PA | $8,236 | 5 |
| , MD | Gastroenterology | Gainesville, FL | $8,219 | 9 |
| , M.D | Specialist | New York, NY | $8,146 | 9 |
| , MD | Gastroenterology | New York, NY | $8,099 | 10 |
| , MD | Gastroenterology | Atlanta, GA | $8,089 | 9 |
| , M.D | Rheumatology | Charlottesville, VA | $8,000 | 1 |
| , M.B.B.S | Gastroenterology | Chicago, IL | $7,851 | 10 |
| , M.D | Gastroenterology | San Diego, CA | $7,805 | 11 |
| Scott Lee | Gastroenterology | Seattle, WA | $7,789 | 10 |
| , MD | Specialist | Pittsburgh, PA | $7,748 | 10 |
| , MD | Gastroenterology | Philadelphia, PA | $7,689 | 9 |
| , M.D | Gastroenterology | Glen Ridge, NJ | $7,619 | 10 |
| , MD | Gastroenterology | Saint Louis, MO | $7,566 | 11 |
| , MD | Gastroenterology | Baltimore, MD | $7,557 | 10 |
| Russell Cohen | Gastroenterology | Burr Ridge, IL | $7,523 | 11 |
| , M.D | Internal Medicine | New York, NY | $7,423 | 7 |
| , M.D | Gastroenterology | New York, NY | $7,313 | 10 |
| , MD | Gastroenterology | Nashville, TN | $7,244 | 9 |
| , MD | Gastroenterology | New York, NY | $7,087 | 8 |
Ad
Manufacturing Companies
- Janssen Research & Development, LLC $7.2M
- Janssen Biotech, Inc. $302,273
- Janssen Scientific Affairs, LLC $38,495
- Janssen Global Services, LLC $30,138
- Johnson & Johnson Health Care Systems Inc. $5,446
- Janssen Pharmaceuticals, Inc $3,520
Product Information
- Type Biological
- Total Payments $7.6M
- Total Doctors 2,389
- Transactions 9,228
About SIMPONI
SIMPONI is a biological associated with $7.6M in payments to 2,389 healthcare providers, recorded across 9,228 transactions in the CMS Open Payments database. The primary manufacturer is Janssen Research & Development, LLC.
Payment data is available from 2017 to 2024. In 2024, $4.4M was paid across 1,881 transactions to 3 doctors.
The most common payment nature for SIMPONI is "Unspecified" ($7.0M, 91.7% of total).
SIMPONI is associated with 17 research studies, including "78934804UCO2001" ($5.7M).